Innovation Pharmaceuticals Inc (IPIX)

[Rdunn88]

Sox, expansion was/is part-of-the-problem. Trying to finance one-drug is difficult for an OTC funded biotech... Adding B was a great move after Merck/Cubist, but became a liability after a botched up-listing. That started the down swing in PPS (spring 2015) which led to Mako (August 2015). 18 months since, Leo failed the shareholders by not addressing the balance sheet. 3 drugs to finance is almost impossible without a strong cash position. Time was eventually going to run out and we're seeing the effects now... Add the Aruda's 16 million shares to Aspires and it's obvious why supply/demand (stock) has failed...